Breaking News

Dollar Tree Agrees to Buy Family Dollar for $74.50 a Share
Tweet TWEET

Cellular Biomedicine Group to Present at New York Stem Cell Summit

Cellular Biomedicine Group to Present at New York Stem Cell Summit  PALO ALTO, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast.  Dr. Cao will speak during the segment, "Practical Methods for Combining Cells and Tissue Engineering". His presentation is titled "Study of Adipose Derived Mesenchymal Precursor Cells Therapy; Re-Join^TM for Osteoarthritis".  About Cellular Biomedicine Group  Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors fromChinaandthe United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com  Forward-Looking Statements  Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.  CONTACT: Sarah Kelly          Director of Corporate Communications, CBMG          +1 650 566-5064          sarah.kelly@cellbiomedgroup.com                   Vivian Chen          Managing Director Investor Relations, Grayling          +1 646 284-9427          cbmg@grayling.com                   OR                   Christopher Chu          Director Investor Relations, Grayling          +1 646 284-9426          cbmg@grayling.com  Cellular Biomedicine Group Inc. Logo